Real-World Data Show Evolocumab Cuts Heart Attack Risk 20% More Than Ezetimibe Post-Statin

The analysis drew on large-scale claims and registry data to compare the PCSK9 inhibitor evolocumab (Repatha) with the cholesterol absorption inhibitor ezetimibe (Zetia) in patients whose LDL remained elevated after statin therapy. Researchers tracked incident myocardial infarction over multi-year follow-up, adjusting for baseline cardiovascular risk and concomitant medications. Absolute event rates were modest, yet the relative difference favored the injectable agent.

This pattern aligns with prior RCTs such as FOURIER for evolocumab and IMPROVE-IT for ezetimibe, both of which demonstrated incremental benefit on top of statins, though head-to-head real-world comparisons had been absent. The 20% figure likely reflects greater LDL reduction achieved with evolocumab, consistent with mechanistic differences in hepatic LDL receptor upregulation versus intestinal absorption blockade.

Limitations include residual confounding inherent to observational designs and lack of randomization or blinded endpoint adjudication. Next steps require a prospective RCT with adjudicated events and cost-effectiveness modeling to determine whether the observed difference justifies broader use or formulary preference.